We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.
- Authors
Jorsal, Anders; Tarnow, Lise; Frystyk, Jan; Lajer, Maria; Flyvbjerg, Allan; Parving, Hans-Henrik; Vionnet, Nathalie; Rossing, Peter
- Abstract
Adiponectin levels are increased in patients with type I diabetes especially in the presence of microangiopathy. Here we determined the predictive value of serum adiponectin levels and 8 adiponectin gene polymorphisms for mortality, cardiovascular events and end-stage renal disease in type I diabetic patients. This prospective, observational follow-up study of type I diabetics consisted of 438 patients with overt diabetic nephropathy that were compared to 440 type I patients with normal albumin excretion. These two groups were followed an average of 8 years and generally matched for gender, age and duration of diabetes. Cox regression analysis of 373 patients showed a covariate-adjusted hazard ratio for all-cause mortality of 1.46 for a change of one standard deviation in log10 of serum adiponectin. There was no association with cardiovascular events; however, serum adiponectin levels predicted end stage renal disease in a covariate-adjusted analysis. Two of eight gene polymorphisms, found in the 878 patients, were associated with increased serum adiponectin levels but none of the polymorphisms were associated with a renal or cardiovascular outcome. These studies show that high serum adiponectin levels predict mortality and progression to end stage renal disease in type I diabetic patients.
- Publication
Kidney international, 2008, Vol 74, Issue 5, p649
- ISSN
1523-1755
- Publication type
Journal Article
- DOI
10.1038/ki.2008.201